INNOVATIVE THERAPIES FOR RHEUMATIC AND SKIN DISEASES

Release Date:  July 12, 2001

NOTICE:  NOT-AR-01-007

RFP AVAILABLE:  NIH-NIAMS-02-01

National Institute of Arthritis and Musculoskeletal and Skin Diseases

This announces the availability of a Broad Agency Announcement (BAA) which 
describes in general terms a research topic and outlines proposal preparation 
requirements.  The purpose of this BAA is to solicit proposals to carry out 
pilot/feasibility (open label, phase I/II) clinical studies to establish the 
safety and gather enough preliminary evidence of efficacy of new and 
innovative therapeutic approaches to rheumatic and skin diseases and to design 
and implement basic or clinical research ancillary projects linked to the 
clinical trial protocol.  The goal of this initiative is to accelerate the 
application of new drugs, biologicals and other non-behavioral interventions 
for the short and long term management of symptoms, signs, systemic and 
structural changes in patients with established rheumatic and skin diseases 
and for the development of strategies for prevention of disease onset, 
progression or structural damage to target organs in patients at high risk.  
New and emerging agents for the treatment of lupus, rheumatoid arthritis, 
scleroderma, myositis, Sjogren"s and other rheumatic diseases are included.  
In the skin diseases area, inflammatory, autoimmune, and genetic skin diseases 
are included as are small trials for innovative therapies on wound healing.  

It is anticipated that three to five cost reimbursement contract awards will 
be made for a maximum period of five years beginning on or about May 30, 2002. 
 The solicitation NIH-NIAMS-BAA-02-01 will be available electronically on or 
about July 23, 2001 and may be accessed through the Internet at the following 
address:  http://www.nih.gov/niams/grants/rfp/rfplist.htm. Proposals will be 
due on or about November 15, 2001. Offerors are responsible for downloading 
their own copy of the solicitation and amendments and for routinely checking 
the Internet site for any possible solicitation amendments that may be issued 
by the Government.  All responsible sources may submit proposals which will be 
considered by the Government.  The North American Industrial Classification 
System (NAICS) code for this acquisition is 541710.  This advertisement does 
not commit the Government to award a contract.

Inquiries may be directed to:

Eileen Webster-Cissel
Chief Contracting Officer
Contracts Management Branch, EP
National Institute of Arthritis and 
Musculoskeletal and Skin Diseases
Natcher Building, Room 5AS13A

45 Center Drive, MSC 6500
Bethesda, Maryland  20892-6500
Telephone: 301-594-2543
FAX: 301-480-5996
Email address: [email protected]

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

			Department of Health and Human Services (HHS)
NIH... Turning Discovery Into Health®